MedTrace Logo

NKG2D CAR-NK & r/rAML

NCT05734898 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-03-03

No results posted yet for this study

Summary

This trial will explore the maximum tolerated dose（MTD）of NKG2D CAR-NK cells in the treatment of relapsed or/and refractory AML in a dose-escalation manner, and observe the clinical safety and efficacy.

Conditions

Interventions

BIOLOGICAL

NKG2D CAR-NK

Lymphodepleting chemotherapy followed by NKG2D CAR-NK infusion

Sponsors & Collaborators

  • Hangzhou Cheetah Cell Therapeutics Co., Ltd

    collaborator OTHER

  • Zhejiang University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-31
Primary Completion
2024-04-30
Completion
2024-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05734898 on ClinicalTrials.gov